开能健康(300272) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 335,819,450.56, representing a 2.33% increase compared to CNY 328,165,726.15 in the same period last year[3]. - Net profit attributable to shareholders decreased by 37.12% to CNY 15,924,291.20 from CNY 25,325,231.55 year-on-year[3]. - Total operating revenue for the current period is $335.82 million, an increase from $328.17 million in the previous period, representing a growth of approximately 2.52%[27]. - Net profit for the current period is $19.77 million, down from $29.55 million in the previous period, reflecting a decrease of approximately 33.23%[28]. - Total comprehensive income for the current period is $20.08 million, down from $30.98 million, a decrease of about 35.14%[29]. - Basic and diluted earnings per share decreased to $0.0281 from $0.0443, a decline of approximately 36.43%[29]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -2,808,939.15, a decline of 109.88% compared to CNY 28,443,512.37 in the previous year[3]. - Cash flow from operating activities showed a net outflow of $2.81 million, contrasting with a net inflow of $28.44 million in the previous period[32]. - The net cash flow from investing activities was CNY 27,806,818.85, a significant improvement compared to CNY -60,243,483.61 in the same period last year[8]. - The company reported a net cash inflow from investing activities of $27.81 million, compared to a net outflow of $60.24 million in the previous period[32]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,132,227,437.91, a slight decrease of 0.03% from CNY 2,132,858,918.73 at the end of the previous year[3]. - The company's total liabilities decreased to CNY 859,921,622.51 from CNY 880,632,931.34, a reduction of about 2.4%[25]. - The total current liabilities decreased to CNY 736,199,211.41 from CNY 753,985,852.40, reflecting a reduction of about 2.4%[24][25]. - The company's equity attributable to shareholders rose to CNY 1,218,676,256.77 from CNY 1,202,418,915.04, indicating an increase of approximately 1.4%[25]. Shareholder Information - The company had a total of 32,293 common shareholders at the end of the reporting period[10]. - The top 10 unrestricted shareholders hold a total of 104,000,000 shares, with the largest shareholder, Qu Jianguo, holding 55,159,552 shares, accounting for approximately 52.94% of the total[11]. - Qu Jianguo's shareholding decreased from 220,638,209 shares to 194,638,209 shares after donating 26,000,000 shares to the Shanghai Jianguo Social Public Welfare Foundation, reducing his ownership percentage from 38.90% to 34.32%[15]. - The Shanghai Jianguo Social Public Welfare Foundation's shareholding increased from 6,896,593 shares to 32,896,593 shares, representing an increase from 1.22% to 5.80% of the total shares[15]. - The company has a total of 166,042,328 restricted shares, with no shares released or added during the reporting period[13]. - Highsen Investment reduced its holdings from 28,343,455 shares to 2,759,3455 shares, representing a decrease of approximately 4.8651% of the total shares during its reduction plan[15]. Operational Highlights - The weighted average return on equity was 1.32%, down from 2.15% in the same period last year, reflecting a decrease of 0.83%[3]. - Financial expenses decreased by 32.07% to CNY 3,320,288.95, primarily due to increased foreign exchange gains compared to the previous year[7]. - Other income decreased by 75.31% to CNY 930,048.18, as there were no similar pandemic subsidies received in the current period[7]. - The company’s inventory increased to CNY 326,269,056.74 from CNY 292,682,613.72, marking a rise of about 11.5%[23][24]. - The company’s accounts receivable slightly decreased to CNY 232,421,351.20 from CNY 236,163,370.79, a decline of approximately 1.6%[23]. - The company’s long-term equity investments decreased to CNY 41,529,104.43 from CNY 42,411,800.06, a decline of approximately 2.1%[24]. - The company’s retained earnings increased to CNY 389,900,569.68 from CNY 373,976,278.48, reflecting an increase of about 4.3%[25]. - Research and development expenses rose to $13.26 million, compared to $10.92 million in the previous period, indicating an increase of about 21.43%[28]. Future Outlook and Developments - The company plans to terminate the non-public issuance of A-shares due to changes in external conditions and comprehensive considerations of its actual situation and development plans[15]. - The company has not disclosed any new product or technology developments in this report[15]. - There are no updates on market expansion or mergers and acquisitions mentioned in the report[15]. - The company has not provided specific future performance guidance or outlook in this report[15].